BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9192448)

  • 1. Large sample tests for binary outcomes in fixed-dose combination drug studies.
    Wang SJ; Hung HM
    Biometrics; 1997 Jun; 53(2):498-503. PubMed ID: 9192448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.
    Lui KJ; Chang KC
    Stat Med; 2008 Jan; 27(1):47-67. PubMed ID: 17708514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Test equality and sample size calculation based on risk difference in a randomized clinical trial with noncompliance and missing outcomes.
    Lui KJ; Chang KC
    Biom J; 2008 Apr; 50(2):224-36. PubMed ID: 18264992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global tests for combination drug studies in factorial trials.
    Hung HM
    Stat Med; 1996 Feb; 15(3):233-47. PubMed ID: 8643882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size determination for comparing several survival curves with unequal allocations.
    Halabi S; Singh B
    Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinded sample size reestimation in non-inferiority trials with binary endpoints.
    Friede T; Mitchell C; Müller-Velten G
    Biom J; 2007 Dec; 49(6):903-16. PubMed ID: 17726715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Power and sample size calculations for discrete bounded outcome scores.
    Tsonaka R; Rizopoulos D; Lesaffre E
    Stat Med; 2006 Dec; 25(24):4241-52. PubMed ID: 16947202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for analyzing multilevel cluster-randomized studies with binary outcomes collected at varying intervals of time.
    Olsen MK; DeLong ER; Oddone EZ; Bosworth HB
    Stat Med; 2008 Dec; 27(29):6055-71. PubMed ID: 18825655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varying cluster sizes in trials with clusters in one treatment arm: sample size adjustments when testing treatment effects with linear mixed models.
    Candel MJ; Van Breukelen GJ
    Stat Med; 2009 Aug; 28(18):2307-24. PubMed ID: 19472169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sample size and statistical power assessing the effect of interventions in the context of mixture distributions with detection limits.
    Chu H; Nie L; Cole SR
    Stat Med; 2006 Aug; 25(15):2647-57. PubMed ID: 16456897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing for the existence of a desirable dose combination.
    Hung HM; Chi GY; Lipicky RJ
    Biometrics; 1993 Mar; 49(1):85-94. PubMed ID: 8513112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size determination for matched-pair equivalence trials using rate ratio.
    Tang NS; Tang ML; Wang SF
    Biostatistics; 2007 Jul; 8(3):625-31. PubMed ID: 17071862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a combination drug with multiple doses in unbalanced factorial design clinical trials.
    Hung HM
    Stat Med; 2000 Aug; 19(16):2079-87. PubMed ID: 10931512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trials with time-to-event outcomes: how much does prespecified covariate adjustment increase power?
    Hernández AV; Eijkemans MJ; Steyerberg EW
    Ann Epidemiol; 2006 Jan; 16(1):41-8. PubMed ID: 16275011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance and sample size requirements of Bayesian methods for binary outcomes in fixed-dose combination drug studies.
    Holt MM; Stamey JD; Seaman JW; Young DM
    J Biopharm Stat; 2009; 19(1):120-32. PubMed ID: 19127471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robustness and power of analysis of covariance applied to ordinal scaled data as arising in randomized controlled trials.
    Sullivan LM; D'Agostino RB
    Stat Med; 2003 Apr; 22(8):1317-34. PubMed ID: 12687657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing the sample size during clinical trials with t-distributed test statistics without inflating the type I error rate.
    Timmesfeld N; Schäfer H; Müller HH
    Stat Med; 2007 May; 26(12):2449-64. PubMed ID: 17080491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-sample performance of the robust score test and its modifications in generalized estimating equations.
    Guo X; Pan W; Connett JE; Hannan PJ; French SA
    Stat Med; 2005 Nov; 24(22):3479-95. PubMed ID: 15977302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reliability, effect size, and responsiveness of health status measures in the design of randomized and cluster-randomized trials.
    Diehr P; Chen L; Patrick D; Feng Z; Yasui Y
    Contemp Clin Trials; 2005 Feb; 26(1):45-58. PubMed ID: 15837452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.